ADD ANI AS A TRUSTED SOURCE
googleads
Menu
Business

Glenmark launches SUTIB (Sunitinib) - priced 96% lower than the innovator brand- Reduces the risk of kidney cancer progression by 58%

Mumbai (Maharashtra) [India], February 16 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India.

ANI Feb 16, 2021 12:22 IST googleads

Glenmark

Mumbai (Maharashtra) [India], February 16 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India.
The drug is launched at a MRP that is approx. 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).
Kidney cancer (renal cell carcinoma) is a disease of uncontrolled cell growth in the lining of small tubes in the kidney. In the past decade, advances in research and drug development have begun to shift the paradigm of this disease.
Sunitinib is an oral multi-kinase inhibitor (MKI), works by blocking several enzymes that promote cell growth. It is useful for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma. It is also approved for patients with certain type of Pancreatic Neuroendocrine Tumours.
According to a Globocan 2020 report, there are close to 40,000 patients with renal cancer in India. For over a decade, Sunitinib has been well recognized as one of the "gold-standard" of care in cases of fast-spreading (metastatic) renal cancer. Research shows that Sunitinib alone has helped reduce the risk of progression of renal cancer by 58 per cent.
"Oncology is an important focus area for Glenmark. We recognize that advanced kidney cancer is a complex disease and patients in India are faced with limited treatment options. Glenmark is committed to bringing targeted and effective medicines at an affordable cost to physicians and their patients," said Alok Malik, Group Vice President & Business Head, India Formulations, commenting on the launch.
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)

Get the App

What to Read Next

Business

Nandita Desai Unveils a Unique Painting Exhibition on Vintage

Nandita Desai Unveils a Unique Painting Exhibition on Vintage

New Delhi [India], March 12: There is something quietly powerful about a window... It neither confines nor escapes. It simply allows us to look, to pause, to breathe between inner and outer worlds. In The Painted Window, multi-award-winning contemporary artist Nandita Desai turns this everyday architectural element into the soul of her fifth solo exhibition, transforming vintage and handcrafted windows into luminous works of art. Running from 16th to 21st March 2026 at the Kamalnayan Bajaj Art Gallery, Nariman Point, Mumbai, the exhibition brings together 50 artworks - windows that look outward at the world, and inward at memory and quiet reflection.

Read More
Business

World Kidney Day: Understanding Kidney Health Before

World Kidney Day: Understanding Kidney Health Before

New Delhi [India], March 12: On the occasion of World Kidney Day, leading kidney experts from across India come together to highlight the growing importance of kidney health and early awareness. As kidney diseases often progress silently without noticeable symptoms in the early stages, timely screening and preventive care are essential. Through their insights, these specialists emphasize the need for healthier lifestyles, regular health monitoring, and greater public awareness to help people protect their kidneys before serious complications arise.

Read More
Business

Livasa Hospitals to Enter Ludhiana with 368-Bed Multi-Speciality

Livasa Hospitals to Enter Ludhiana with 368-Bed Multi-Speciality

Ludhiana (Punjab) [India], March 12: Livasa Hospitals announces its expansion into Ludhiana with the development of a 368-bed multi-speciality tertiary care hospital, marking a significant step in strengthening its healthcare network across Punjab. The new facility will support Livasa's long-term vision of expanding its healthcare footprint to nearly 2,000 beds and improving access to advanced medical care for patients across the region.

Read More
Business

Aarti Industries Limited Secures USD 150 Million Supply

Aarti Industries Limited Secures USD 150 Million Supply

Mumbai (Maharashtra) [India], March 12: Aarti Industries Limited (AIL), a leading global manufacturer of speciality chemicals, has entered into a multi-year supply agreement with a top global agrochemical innovator for the supply of a critical agrochemical intermediate used in crop protection formulations. This agreement elevates the current annual engagement to a structured supply contract through 31st March 2030, with a significant increase in volumes.

Read More
Business

Wizz Financial Completes First Stablecoin-Powered Cross-Border

Wizz Financial Completes First Stablecoin-Powered Cross-Border

Dubai [UAE], March 12: Wizz Financial, the global fintech company specializing in cross-border payments and digital wallets, today announced the completion of its first stablecoin-powered cross-border remittance and treasury transaction originating from the United States, with capabilities into 80 countries, in partnership with BitGo Bank & Trust, N.A. ("BitGo"), an OCC-regulated digital asset trust bank and subsidiary of BitGo Holdings, Inc. (NYSE: BTGO). Through the partnership, Wizz Financial is utilizing BitGo's institutional-grade wallet infrastructure and e-trade services to facilitate the conversion of fiat currency into stablecoins, enabling near-real-time settlement, enhanced liquidity management, and compliant, scalable cross-border remittance flows across its global network as new corridors are progressively launched.

Read More
Home About Us Our Products Advertise Contact Us Terms & Condition Privacy Policy

Copyright © aninews.in | All Rights Reserved.